Patents Examined by Jared Barsky
  • Preparation and uses of obeticholic acid
    Patent number: 10047117
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 14, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
    Patent number: 10022448
    Abstract: A composition comprising: a benefit agent; at least one polymer including a polycaprolactone polymer; at least one lower alcohol; and at least one co-solvent; and a method for enhancing topical delivery of a benefit agent is disclosed.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: July 17, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Ying Sun, Anna Gosiewska, Dennis D. Jamiolkowski, Jeffrey M. Wu
  • 3-methanesulfonylpropionitrile for treating inflammation and pain
    Patent number: 9492420
    Abstract: The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: November 15, 2016
    Assignee: OLATEC THERAPEUTICS LLC
    Inventor: Joseph St. Laurent
  • Use of cinnabarinic acid as a modulator of immune responses in autoimmune disorders
    Patent number: 9486457
    Abstract: The present invention provides compounds and methods for preventing and treating an immune disorder in a subject.
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: November 8, 2016
    Assignee: The Regents of the University of California
    Inventor: Jeffrey Eron Mold
  • Monohydrate of azaadamantane derivatives
    Patent number: 9464078
    Abstract: The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: October 11, 2016
    Assignee: AbbVie Inc.
    Inventors: Shuang Chen, James J. Napier, Geoff G. Z. Zhang, Paul J. Brackemeyer
  • Synthesis and growth regulatory activity of a prototype member of a new family of aminothiol radioprotectors
    Patent number: 9458100
    Abstract: The synthesis, growth inhibition and radioprotective activity of the PrC-210 aminothiol, 3-(methyl-amino)-2-((methylamino)methyl)propane-1-thiol, and its polyamine and thiolated polyamine progenitors are reported. All of the molecules significantly inhibited growth of cultured normal human fibroblasts. The combination of an ROS-scavenging thiol group and a positively charged alkyl-amine backbone provided the most radioprotective aminothiol molecule.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: October 4, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: William E. Fahl